Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 08/20 06:39:47 pm
72.295 USD   -0.86%
08/17Bach proposes CAR T payment options for CMS
AQ
08/14GILEAD SCIENCES : Announces Executive Promotions
BU
08/10GILEAD SCIENCES : China National Drug Administration Approves Gilead..
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Sector news Bio Therapeutic Drugs
08/16REGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
08/03Roche Drug for Brain Disease Granted European Fast-Track
DJ
08/02Regeneron Closes Up 7% After 2Q Earnings Beat -- Data Talk
DJ
08/02REGENERON PHARMACEUTICALS : Beats Earnings Estimates
DJ
07/31UNITED THERAPEUTICS : Medtronic Get FDA OK for Remodulin Implantable System
DJ
07/27JOHNSON & JOHNSON : J&J's Janssen Gets Positive CHMP Opinion for Darzalex as Fro..
DJ
07/26Upbeat Roche bests rival Novartis as new drugs fuel growth
RE
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/11LIGAND PHARMACEUTICALS : Janssen Enter R&D Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
05/25Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/03Teva raises 2018 outlook, expects migraine drug approval by year-end
RE
05/03Samsung BioLogics' shares slide again; unit's valuation jump questioned
RE
04/06Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck's Keytruda
DJ
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
RE
03/11REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
03/10REGENERON PHARMACEUTICALS : and Sanofi Plan to Cut Cholesterol Drug Price in Exc..
DJ
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
02/08REGENERON PHARMACEUTICALS : Collaborations Drive Revenue Increase at Regeneron -..
DJ
01/30Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
RE
01/22Biotech M&A takes off as Sanofi and Celgene spend $20 billion
RE
01/22New drugs recast $10 billion haemophilia market as Sanofi swoops in
RE
01/12Drugmakers see a pricing blueprint in an $850,000 gene therapy
RE
01/08SANOFI : and Regeneron boost investment in cancer drug cemiplimab
RE
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
DJ
01/07ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance
DJ
01/05Best week since April for European shares as UK, Swiss indexes hit records
RE
2017U.S. tax cuts mix pleasure and pain for Europe's dollar earners
RE
2017STOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
DJ
2017ALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
DJ
2017France's Sanofi pins hopes on new drugs after setbacks
RE
2017Sanofi investors hungry for drug progress and deal news
RE
2017Tax-loss selling to pressure 2017's losers in December
RE
2017GENMAB : and J&J 'love' partnership as some ponder takeover
RE
2017BIOGEN : Alkermes Join Forces for Multiple Sclerosis Drug
DJ
2017Regeneron drops eye-drug combination as Novartis chases Eylea
RE
2017Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
RE
2017Recovery rally for European stocks leaves oil sector behind
RE
2017Poor earnings updates keep European shares at seven-week low
RE
2017NOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
DJ
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 21 360 M
EBIT 2018 11 160 M
Net income 2018 6 650 M
Debt 2018 12 363 M
Yield 2018 3,12%
P/E ratio 2018 14,19
P/E ratio 2019 13,24
EV / Sales 2018 5,00x
EV / Sales 2019 4,95x
Capitalization 94 529 M